Key facts
- Compass Therapeutics, Inc. filed a DEF 14A proxy statement on June 3.
- The filing relates to the company's annual shareholder meeting.
- It contains information on executive compensation and director nominations.
Compass Therapeutics, Inc. submitted its definitive proxy statement (DEF 14A) to the Securities and Exchange Commission (SEC) on June 3. This filing is a prerequisite for the company's annual shareholder meeting, providing comprehensive details on corporate governance. Shareholders can review information regarding executive compensation, the proposed slate of directors, and any other matters requiring a shareholder vote. The DEF 14A ensures shareholders are informed to make educated decisions during the voting process at the annual meeting.